Castle Biosciences Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript
Good morning. This is Paul Knight, the life science and diagnostics analyst at KeyBanc. It's a pleasure to have Castle Biosciences here today. We have the CEO, Derek Maetzold; Chief Financial Officer, Frank Stokes; and Head of Investor Relations, Camilla Zuckero. We'll have a presentation by Castle. We will then open it up for some Q&A. (Conference Instructions)
So Frank, thanks for your time -- Derek, thanks for your time, and we'll let you do the overview.
Excellent. Thank you, Paul, and thank you to the KeyBanc team for inviting us here to participate in your 2022 Life Sciences & MedTech Investor Forum. It's a pleasure to be here. We just put together a couple of slides to kind of give the audience just a quick snapshot of who Castle Biosciences is, how we closed out 2021, and some near-term milestones and 2022 guidance, so we can set that as a table setter to go forward here.
Disclaimer slide. Our vision is to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |